The study will evaluate OKG-0301 eye drops, to evaluate the reduction of the signs and symptoms of adenoviral conjunctivitis, as well as the overall length of infection.
Results from our RUBY Trial demonstrate that OKG-0301 is a safe, effective and dose-responsive anti-viral medication.